7-Oxodehydroepiandrosterone 3-Acetate Adenosine Tr
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- 7-Oxodehydroepiandrosterone 3-Acetate Adenosine Tr
- Complex Multi-Ingredient Biological Product (16 Components): Insufficient Data for Repurposing Evaluation
Complex Multi-Ingredient Biological Product (16 Components): Insufficient Data for Repurposing Evaluation
One-Sentence Summary
This entry corresponds to a complex 16-ingredient product containing botanical extracts, animal organ preparations, and biological compounds, consistent with a homeopathic or organotherapy formulation. The TxGNN model did not generate any predicted new indications for this product — most likely because no DrugBank ID could be assigned to the multi-ingredient mixture and individual components could not be independently mapped in the knowledge graph. Given the complete absence of regulatory approval, mechanism data, and model predictions, no evidence-based repurposing evaluation can be conducted at this time.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no regulatory license found) |
| Predicted New Indication | None (TxGNN returned no predictions) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction not available; no actual studies identified |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why No Prediction Was Generated
This product contains 16 distinct components spanning three categories:
Botanical / Herbal components: Cynanchum vincetoxicum root, Echinacea angustifolia, Gamboge, Phytolacca americana root, Strychnos nux-vomica seed
Animal organ preparations (organotherapy): Pork kidney, pork liver, pork hypothalamus (Sus scrofa hypothalamus), pork pancreas (Sus scrofa pancreas), pork insulin
Other biological and chemical components: 7-Oxodehydroepiandrosterone 3-acetate, adenosine triphosphate disodium, lactic acid (L-), methylcobalamin, Proteus vulgaris, graphite
This ingredient profile is consistent with a homeopathic complex remedy or biological organotherapy preparation — product classes that are fundamentally incompatible with the TxGNN repurposing pipeline for two reasons:
- No DrugBank ID available: TxGNN requires a single mapped DrugBank entity as input. Multi-ingredient homeopathic mixtures cannot be mapped as a unit, and many individual components (e.g., Gamboge, graphite, Sus scrofa hypothalamus) have no DrugBank representation.
- No defined pharmacological mechanism: These products do not act through a singular receptor or enzyme target pathway, making knowledge-graph traversal and disease-node linking impossible.
The query log confirms that the DrugBank lookup returned a result count of 1, but no DrugBank ID was assigned (drugbank_id: null), indicating an inconclusive or partial match that did not qualify for downstream prediction.
Clinical Trial Evidence
Currently no related clinical trials registered for this multi-ingredient combination in ClinicalTrials.gov or ICTRP.
Literature Evidence
Currently no related literature available for this specific multi-ingredient combination as a single therapeutic entity.
US Market Information
This product has 0 regulatory licenses in the United States. No NDA, ANDA, or BLA records are associated with this multi-ingredient combination.
Safety Considerations
Please refer to the package insert for safety information.
Note: Several individual components carry inherent safety concerns that would require independent review before any clinical use:
- Strychnos nux-vomica seed contains strychnine and brucine — potent convulsants with a narrow therapeutic index.
- Gamboge is a known GI irritant and has historically been associated with toxicity at higher doses.
- Phytolacca americana root (pokeweed) contains phytolaccatoxin and has potential mitogenic and toxic effects.
- Pork insulin carries risk of hypoglycaemia and immunogenic reactions.
Conclusion and Next Steps
Decision: Hold
Rationale: This product is a homeopathic/organotherapy complex that the TxGNN pipeline cannot process — there is no DrugBank ID, no mapped mechanism of action, no regulatory approval, and no predicted indication. The minimum preconditions for a repurposing evaluation are not met.
To proceed, the following is needed:
- Clarify product identity: Confirm the brand name, manufacturer, and intended use category (homeopathic vs. conventional). This will determine whether the product is in scope for TxGNN-based repurposing at all.
- Decompose into single active ingredients: If any individual component (e.g., methylcobalamin, ATP disodium, 7-oxo-DHEA acetate) is the primary active entity, re-submit that compound as a standalone query.
- Assess regulatory pathway separately: Homeopathic products are regulated under distinct frameworks (e.g., FDA OTC Homeopathic Drug Products Guidance); the TxGNN repurposing framework is not designed to evaluate these.
- Resolve data gaps DG001 and DG002: Safety warnings and MOA cannot be obtained until the product identity is confirmed.
- Exclude from current pipeline: Unless decomposed into individual components, this entry should be flagged as out-of-scope for the TxGNN drug repurposing workflow and removed from the active candidate queue.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.